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The diagnosis of childhood psychosis raises a host of
unresolved problems, despite the Diagnostic and Sta-
tistical Manual Of Mental Disorders, 4th edition, Text
Revision (DSM-IV-TR) giving identical symptoms and
definitions for children, adolescents, and adults. The
fantasy lives of children, and issues of developing lan-
guage and cognition (including retardation), all impair
diagnostic accuracy, particularly when differentiating
between childhood-onset schizophrenia (COS) (≤ 12
years), bipolar affective disorder, major depressive dis-
order, and even obsessive-compulsive disorder and
attention-deficit/hyperactivity disorder: the catch-all
classification, psychosis not otherwise specified (PNOS),
is always available for conundra that prove unsolvable.
Typical if nonpathognomonic features include neu-
rocognitive difficulties. Multiple screening instruments
and specialized versions of semistructured diagnostic
interviews are available. Although smooth-pursuit eye-
tracking movements may prove a genetic marker for
COS, etiologies are likely to be oligogenetic rather than
related to a single gene. No specific biological markers
or neuroimages have been identified. As such, psy-
choses may be indicative of a more general pattern of
brain dysfunction. Drug treatments are largely based
on the adult literature because of a dearth of con-
trolled data below age 18. There are still no rigorous
studies of psychosocial treatments and psychotherapy
specific to childhood psychosis.
sychosis presenting in childhood and adolescence
has been a controversial topic throughout the history of the
field of child psychiatry because of the conundrum of diag-
nostic clarity.As the necessity of diagnostic accuracy informs
treatment as well as prognosis, an important question is
whether the various psychoses of childhood are contigu-
ous with the adult forms,or whether the symptoms labeled
as psychotic in youth, particularly in prepubertal children,
are exactly the same as those seen in adults. Historically,
the definition of psychosis in children and adolescents has
been particularly vague because of confusion regarding the
developmentally appropriate role of imagination and fan-
tasy in children and adolescents with and without psychi-
atric disorders.Formulations of “childhood psychosis”and
psychosis were originally conceptualized as part of the spec-
trum of the pervasive developmental disorders, but cur-
rently, symptoms of psychosis and definitions of psychotic
disorders do not differ for children,adolescents,or adults in
the Diagnostic and Statistical Manual of Mental Disorders,4th
edition,Text Revision (DSM-IV-TR).
1
The word “psychosis”applies to a state of being (ie,a psy-
chotic state) as well as distinct diagnostic entities.The psy-
chotic symptoms described in DSM-IV-TR include disor-
ganization or gross disturbance of thought form or speech,
thought content, or behavior, or extreme negativism. A
psychotic symptom,or symptom cluster,is associated with
a specific disorder as defined by a certain number of symp-
toms occurring over a circumscribed duration of time with
demonstrated impairment. Hallucinations and delusions
are usually thought to establish the diagnosis of psychosis.
However,neither of these symptoms are pathonomonic of
psychosis, as they can occur in other organic medical or
neurological conditions, such as dementias or complica-
tions of seizure disorders.Normal children with active fan-
tasy lives can often misperceive their thoughts as actual
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State of the artevents and can insist in a firm way that a thought or a
dream actually occurred, which would seem to meet the
definition of hallucination and delusion.
Schizophrenia is perhaps the best studied of the adult
psychiatric disorders.Its symptoms and phenomenology
are well established,and there is a comparative wealth of
neuroimaging,genetic,and neurocognitive research that
informs the understanding of this illness.When the crite-
ria are applied to older adolescents, an age group when
first episodes often occur,the diagnosis is often reliable.
However, in the younger age group, the issues of devel-
oping language and cognition interfere with the depend-
ability of diagnostic accuracy.The adult form of schizo-
phrenia is not a monadic entity,but rather appears to be
a collection of etiologically distinct disorders with similar
clinical presentations. No consistent or gross neu-
ropathology that identifies the illness.
These issues also apply to bipolar affective disorder
(BPAD). The template of symptoms and presentation
can apply easily to older adolescents as well as adults,
but the situation is less clear in younger children.
Because of variability of symptom presentation, psychotic
symptoms that can occur within the spectrum comprising
childhood-onset schizophrenia (COS,age of onset ≤ 12 years),
eg, schizophreniform disorder, schizotypal disorder, and
schizoaffective disorder,are difficult to distinguish from psy-
chotic and nonpsychotic symptoms related to BPAD and
major depressive disorder (MDD). Psychotic symptoms in
children and adolescents need to be differentiated from other,
intense, repetitive, but nonpsychotic phenomena, such as
obsessions related to obsessive-compulsive disorder (OCD),
anticipatory anxiety related to non-OCD anxiety disorders,
rumination related to depression, perseverative thoughts
related to developmental disorders, simple disorganization
related to attention-deficit/hyperactivity disorder (ADHD),
and overvalued ideas.In addition,language deficits and cog-
nitive deficits related to mental retardation may suggest psy-
chosis in nonpsychotic children. Furthermore, nonspecific
symptoms,such as anxiety,distractibility,and irritability,may
precede a psychotic break and confuse diagnosis based on
course of illness.Psychosis not otherwise specified (PNOS) is
intended to classify psychotic symptoms not associated with
COS, BPAD, or MDD. Accurate and reliable diagnosis of
psychosis during childhood remains elusive,and is indicative
of the necessity for more thoughtful study.
Prevalence
Sparse epidemiological data suggest that psychosis is rare
in children. Schizophrenia with onset during middle to
late adolescence is fairly common, with 1% prevalence,
compared with the extremely rare COS with a prevalence
of 0.2 to 0.4/10 000.
2 The largest study of COS to date,
involving 1400 national referrals to the National Institute
of Mental Health (NIMH) over 10 years, identified 260
children with psychosis.
3 Only 71 patients met criteria for
COS at study entry,
3 whereas only 54 children retained
the diagnosis of COS (Rapoport JL, personal communi-
cation,2000).In contrast,MDD may occur in 1% of chil-
dren and 5% of adolescents,
4,5 whereas BPAD occurs in
1% to 2% of adolescents.
6,7 Mood disorders with psy-
chosis are considerably rarer in children and adolescents.
The prevalence of psychosis NOS and BPAD in children
is hard to ascertain because of controversy about validity.
Phenomenology
Childhood-onset schizophrenia
As with schizophrenia diagnosed at any age, COS pre-
sents with two types of symptom clusters, positive psy-
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Selected abbreviations and acronyms
ADHD attention-deficit/hyperactivity disorder 
AE adverse effect
BPAD bipolar affective disorder
BPRS Brief Psychiatric Rating Scale 
CDRS Child Depression Rating Scale
CGAF Clinical Global Assessment of Function
CGI-I Clinical Global Impressions–Improvement
CGI-S Clinical Global Impressions–Severity
COS childhood-onset schizophrenia
DICA Diagnostic Interview for Children and Adolescents
DISC Diagnostic Interview Schedule for Children
EPS extrapyramidal symptom
K-PANSS Kiddie Version of the Positive and Negative
Symptoms of Schizophrenia
K-SADS Schedule for Affective Disorders and Schizo-
phrenia for School-Aged Children
MDD major depressive disorder
MRI magnetic resonance imaging 
1H-MRS magnetic resonance spectroscopy
OCD obsessive-compulsive disorder
PNOS psychosis not otherwise specified
Y-MRS Young Mania Rating Scale81
chotic symptoms and negative psychotic symptoms. Posi-
tive symptoms (phenomena that are present and should
not be) in children include gross disturbance of thought
process or thought content, whereas delusions likely
appear with increasing developmental age.Negative symp-
toms (phenomena that are not present and should be)
include flat affect, anergy, and paucity of speech and
thought.
2 Prepubertal children with psychosis seem to have
less systematic delusions and lower incidence of catatonic
symptoms, but are capable of exhibiting hallucinations,
disordered thought process,and flattened affect.
8 Insidious
course of COS and onset prior to age 12 years are predic-
tors of a more serious outcome.
9 Other features of COS
that contribute to poor outcome include severity of posi-
tive and negative symptoms in acute episodes,
10,11 lower
cognitive functioning,
12 and premorbid dysfunction in lan-
guage,motor development,and social relatedness.
13-15
Bipolar disorder
The clinical picture of pediatric BPAD ranges from
symptoms resembling severe ADHD to symptoms
resembling paranoid schizophrenia. Children with
BPAD often initially present with either rapid cycling or
mixed state symptoms rather than an insidious onset as
described with COS.
6 Children and adolescents with
mania present with pressured speech, racing thoughts,
elation, and increased risk-taking activities, which may
include developmentally inappropriate or situationally
inappropriate sexuality.When BPAD has first onset dur-
ing adolescence, psychosis is typically the presenting
symptom and an adult-like cycling pattern follows.
16
Grandiosity, a hallmark symptom of BPAD at any age,
may be disguised by developmental age,as prepubertal
children with BPAD appear severely oppositional
instead of obviously grandiose.Unfortunately,the clini-
cal distinction between the grandiosity of BPAD and
the paranoia of schizophrenia is often too hard to dis-
tinguish.Mood symptoms,such as euphoria or irritabil-
ity, may also be disguised by developmental age. One
researcher described poorly formed euphoria in manic
adolescents that resembles a carefree, “spacey,” or
“delirious-like” quality that may present as disordered
thought process (Popper C, personal communication,
2001). Interpersonal difficulties may exist secondary to
symptoms associated with BPAD; however, children
with BPAD do not seem to have the social withdrawal
or the impoverished social relatedness seen in COS.
While these children may present with language disor-
ders or learning disabilities, they do not appear to have
the extent of deficits seen in children with schizophrenia.
Children and adolescents with BPAD involving severe
mood instability have a more chronic and treatment-
refractory course then adults.
17,18 Over half of all bipolar
adolescent patients with prolonged episodes show sig-
nificant functional impairment in the long term com-
pared with their premorbid state. When children with
premorbid social withdrawal and poor interpersonal
relationships were compared in terms of diagnosis,chil-
dren with BPAD had lower rates of positive and nega-
tive symptoms at 1-year follow-up than children diag-
nosed with schizophrenia or schizoaffective disorder.
19
Major depression
Flat affect related to psychosis is often difficult to dis-
tinguish from severely depressed or restricted affect at
any age; similarly, anergy of psychosis may be hard to
distinguish from psychomotor retardation of depression.
Children who present with a psychotic depression may
also appear to have impoverished thoughts and social
withdrawal;however,the mood symptoms are expected
to improve with resolution of the episode. In contrast,
the negative symptoms of schizophrenia may not
improve with resolution of the episode.In children pre-
senting with psychosis in the context of depression,50%
to 60% will develop BPAD, and their risk for suicide is
markedly increased.
20,21
Schizoaffective disorder
As the name implies, schizoaffective disorder shares
many symptoms with the affective disorders, which can
complicate the diagnosis. In the initial phases of psy-
chotic illness in children and adolescents,affective symp-
toms related to adjustment and demoralization may
overshadow the presence of psychotic symptoms.
According to DSM-IV-TR, delusions or hallucinations
of 2 weeks’ duration must occur in the absence of mood
symptoms to distinguish schizoaffective disorder from
a mood disorder with psychotic features. Traditionally,
the diagnosis of schizophrenia has relied on the pres-
ence of bizarre hallucinations or delusions instead of
mood-congruent hallucinations or delusions related to
BPAD or MDD.However,the determination of “mood
congruent”at times appears too subjective.For instance,
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youngsters who initially present with mood-incongru-
ent hallucinations, marked thought disorder, and para-
noia have later been diagnosed with BPAD as promi-
nent mood cycling appeared.
18 In contrast,some children
initially diagnosed with schizoaffective disorder on the
basis of prominent mood symptoms later develop sig-
nificant symptoms of thought disorder, while the mood
symptoms only accompany the psychotic episodes.
Schizoaffective disorder is associated with the poorest
outcome and chronic impairment in children.
17
Psychosis not otherwise specified
The diagnostic category of PNOS may be used by default
when full criteria are lacking for psychotic disorders in
the schizophrenic or mood disorders spectrum.There are
divergent opinions about the validity of PNOS.The diag-
nosis is sometimes given to children who present with
self-reports of hallucinations and/or delusions in the
absence of a formal thought disorder, severe mood dis-
turbance, or other clinical context suggesting a state of
psychosis.The validity of self-reported hallucinations and
delusions was questioned in a study of children diagnosed
with PNOS with brief psychotic episodes and hallucina-
tions, but without formal thought disorder or psychotic
behaviors.
22 One group of researchers found high inci-
dence of physical/sexual abuse in children diagnosed with
PNOS,
23 and suggested a scenario of dissociative symp-
toms accounting for the self-report symptoms.The NIMH
study group decided that children who did not meet cri-
teria for COS were better served with a diagnosis of
PNOS,and described a subgroup called multidimension-
ally impaired disorder (MDI),
24 which has also been called
multiplex developmental disorder,
25 for a group of chil-
dren presenting with brief transient psychotic symptoms,
emotional lability,normal social interest with poor inter-
personal skills, and multiple deficits in information pro-
cessing.
26 Preliminary follow-up suggests that this cohort
does not progress to a more severe psychotic disorder;
however, there is a high rate of schizophrenia spectrum
disorders in their first-degree relatives.There are also sim-
ilarities in brain morphologic abnormalities between the
MDI group and children with schizophrenia.
27
Schizotypal disorder
The inclusion of a personality disorder in a discussion of
childhood psychosis reflects the controversy of psychosis
in children. Researchers and clinicians are generally
uncomfortable diagnosing personality disorders in the
pediatric population, and the distinction of state versus
trait symptoms remains controversial at all ages. Poor
social relations,odd thinking,and perceptual problems,
such as illusions and ideas of reference without actual
psychosis,are the characteristics of schizotypal disorder
as defined in adults. In one study of adolescents with
schizophrenia, the social skills of the adolescents mir-
rored those reported in adults with schizotypal person-
ality disorder.
28 These adolescents had more difficulty
in labeling positive emotions than other emotions and
performed worse than a control group on social role-
playing tasks. Neuropsychological deficits correlated
with the presence of negative signs in adolescents with
schizotypal personality disorder.
29 Subjects who exhib-
ited more negative signs had a high association with dys-
morphia and lower cognitive ability, suggesting early
developmental instability.
30
Features associated 
with psychosis in children 
Neurodevelopmental delays
Children with COS have been described as having
developmental differences as early as infancy. These
children show abnormal or delayed development
including gross and fine motor delays, hypotonia, poor
coordination, sensory integration difficulties, and lan-
guage delays.
9,31,32These children also exhibit stereotyp-
ies, such as hand flapping, perseverative smelling, and
touching, ie, symptoms typically seen in children with
pervasive developmental disorders.These children also
have attentional problems,distractibility,and other dis-
inhibitions of executive functioning,which meet criteria
for ADHD, possibly an indicator of poor prognosis.
33
Children who have other schizophrenia spectrum dis-
orders also have a history of developmental delays and
cognitive deficits.
Children with COS have a high incidence of language
disorders,not only expressive and receptive,but also with
specific impairments and deficits that directly contribute
to thought disorder and disorganization. Children with
delayed expressive and receptive language development
were able to catch up with their peers,although they con-
tinued to have deficits in their linguistic capacities.
34 Chil-
dren with schizophrenia use fewer linguistic or cohesive
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devices to connect ideas expressed within and across sen-
tences compared with a sample of children without schiz-
ophrenia.
35 They also exhibit decreased use of conjunc-
tions, referential cohesions such as pronouns, lexical
cohesions illustrated by the use of antonyms and syn-
onyms, and increased use of ellipses (eg, deletion of
words or phrases whose referent is located in the previ-
ous utterance). Such difficulties in conveying language
lead to three components of thought disorder:exophora,
which is the diversion of speech from the context of a
conversation to the immediate environment;loose asso-
ciations or topic maintenance; and cohesion.
36,37 In a
larger study of schizophrenic children who were com-
pared with a control group, children with COS are dis-
tinctly impaired in their ability to organize their thinking,
present adequate reasoning,and prepare the listener for
a change in the topic of conversation above and beyond
differences in mental age.
38 Children with COS make
more references in their conversation to the immediate
situation rather than to the context of the conversation.
They are also unable to use clarifying references on a
consistent basis so that the listener can understand the
context. These deficits may be related to the freedom
from distractibility factor of the Wechsler Intelligence
Scale for Children–Revised (WISC-R) rather than global
intellectual deficits.
39 Subjects with COS and premorbid
speech and language impairments had a higher familial
loading for schizophrenia spectrum disorders as well as
more obstetrical complications,and the relatives of these
children had worse smooth-pursuit eye-tracking move-
ments.
40 These data suggest that the pathophysiology of
schizophrenia involves abnormal development of lan-
guage-related functions.
There is little in the literature about developmental dif-
ficulties in children with psychotic mood disorders.Chil-
dren with early onset BPAD show evidence of delayed
language,social,and motor development.
41
Neurocognition
Children with COS as a group appear to have lower IQ
scores than the normal population.
12 It has been specu-
lated on the basis of neurocognitive studies that these
lower IQ scores reflect prodromal neurocognitive deficits,
rather than exposure to environmental factors.
42 Cognitive
functioning, such as attention, memory, and motor func-
tioning, has been found to be abnormal in many schizo-
phrenic subjects. Since the above cognitive findings are
similar to findings in children with ADHD, researchers
compared these two groups with each other and with nor-
mal controls. Adolescents with schizophrenia showed
more deficits in visual memory than ADHD or normal
controls. In addition, they had lower scores in abstrac-
tion-flexibility, spatial organization, and motor function.
Subjects with ADHD had significantly worse auditory
processing and distractibility, which may indicate selec-
tive impairments in visual memory specifically related to
schizophrenia.
43 In addition, the subjects with COS had
more difficulty on tests requiring shifting of sets,which is
seen as a function of working memory. Furthermore, it
has been reported that subjects can show impairments
on the span of apprehension task when they are acutely
psychotic, as well as interepisode.
44 This neurocognitive
test is a measure of thought disorder.Deficits in both ver-
bal and spatial working memory lead to limited informa-
tion-processing capacity in children with COS.
45,46
The IQ of adolescent subjects with COS was studied to
determine whether the postpsychotic decline in full-scale
IQ is secondary to a dementing process or whether it
reflects a failure to acquire new information and skills.
47
Those areas in which scores declined significantly
postpsychosis were picture arrangements, information,
and block design. This research group also used mag-
netic resonance imaging (MRI) to detect changes in the
brain anatomy and found a significant correlation
between decrease in hippocampal volume with a smaller
increase in the raw score on the information subtest.
The authors concluded that the IQ decline during ado-
lescence of subjects with COS is secondary to an inabil-
ity to acquire new information and skills.
Studies of the families of children with COS indicate
first-degree relatives and other relatives have similar
neurocognitive difficulties.Nearly 30% of nonpsychotic
parents of COS probands showed neurocognitive
impairments.
46 Children of schizophrenic parents,affec-
tively ill parents,and psychiatrically normal parents have
been studied to search for predictors of future illness.
48
Measures of attention deviance, verbal memory, and
gross motor skills were utilized based on studies of rela-
tives of adult psychiatric probands.This report suggests
that these may be phenotypic indicators, as the deficits
were present before clinical symptoms, independent of
the illness date, more prevalent in relatives of schizo-
phrenic patients than in comparison subjects, and com-
paratively specific to the risk for schizophrenia versus
the risk for affective disorders. Verbal memory andattention were tested over several evaluations and found
to have longitudinal stability and persistence of impair-
ment. These neurobehavioral deficits may represent a
prodromal indicator of risk if they are sustained.
Children with COS and children with PNOS shared a
similar pattern of generalized cognitive deficits including
deficits in attention,learning,and abstraction,which are
also observed in adult patients with schizophrenia.
49
Learning disabilities and language disorders occurred
in children with BPAD during the illness and between
episodes.
50 There was a significant discrepancy between
the verbal IQs of children of bipolar parents and normal
controls.
51
These studies viewed as a whole would suggest that the
syndromes of the psychoses, and in particular that of
COS, are indicative of a more general pattern of brain
dysfunction. If these findings can be replicated, then
they would contribute to a theory of neurodevelopmen-
tal pathogenesis that investigators in adult psychiatry
are debating.
Diagnostic assessments
In general, the psychiatric assessment of psychosis in
children follows the model for comprehensive psychi-
atric assessment of children and adolescents, which
includes a medical and psychiatric history,mental status
examination, physical examination, and standardized
psychiatric assessment instruments.The psychiatric his-
tory focusing on psychotic symptoms must carefully
delineate family history, course of illness, and compre-
hensive review of symptoms. Particularly, the extent,
nuance, and context of the psychotic phenomena must
be clarified to identify mood congruence, mood incon-
gruence,bizarre content,and stability of symptoms.Most
importantly,psychosis must be ruled out when the phe-
nomenology does not hold under close diagnostic
scrutiny.While no medical assessment procedure is diag-
nostic of COS or any other psychiatric condition associ-
ated with psychosis, use of imaging studies, electroen-
cephalography, and laboratory tests may help detect
medical conditions associated with psychosis in children
and adolescents.
Screening instruments
Before a formal diagnosis is established,and in addition
to using a reliable and valid structured or semistruc-
tured interview, screening instruments may help iden-
tify psychiatric disorders associated with psychotic symp-
toms. Screening instruments for depression in children
and adolescents include the Children’s Depression
Inventory,
52 which has normative data for children and
adolescents.The Young Mania Rating Scale (Y-MRS)
53
has normative data for adolescents with BPAD.There is
no screen with normative data for children with schizo-
phrenia or other psychotic disorders.
Semistructured diagnostic interviews
The stringent use of adult criteria to delineate psychotic
symptoms in children and adolescents,and the develop-
ment of reliable and valid rating instruments to clarify
the presence and severity of these symptoms suggest
that some children with psychotic illness are exhibiting
an early manifestation of the adult form of the illness.
Homogeneous diagnostic criteria have demonstrated
that COS can be diagnosed using adult standards,
54,55 and
studies using DSM-III and DSM-III-R criteria confirmed
these findings.
9,56 Rigorous application of DSM-III cri-
teria can accurately diagnose childhood BPAD.
57 Stan-
dardized interviews, such as the Schedule for Affective
Disorders and Schizophrenia for School-Aged Chil-
dren–Present and Lifetime Version (K-SADS-PL),
58 the
Diagnostic Interview for Children and Adolescents
(DICA),
59 and the Diagnostic Interview Schedule for
Children (DISC)
60 are reliable and valid measures for
diagnosing MDD, BPAD, COS, and other psychiatric
disorders in childhood that present with psychosis.The
K-SADS is the probably the gold standard. Currently,
specialized versions of the K-SADS, such as the Wash-
ington University at Saint Louis Kiddie Schedule for
Affective Disorders and Schizophrenia (WASH-U-K-
SADS),offer the advantage of focused diagnosis in pre-
pubertal and early adolescent manifestations of mania
with and without rapid cycling.
61
The real importance of the standardized diagnostic
instruments is establishing diagnostic stability,symptom
dimensions,clinical characteristics,and predictive valid-
ity.Long-term studies utilizing the same diagnostic tests
over time
62,63 indicate that there is stability of symptoms
with the differentiation of features of the various ill-
nesses and establishment of the clinical characteristics of
the individual illnesses.A more recent example of symp-
tom predictability involved a prospective study of a birth
cohort (n=761), who were given structured diagnostic
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64
The group was divided into those who had weak symp-
toms and strong symptoms based on the reports of hal-
lucinations or delusions,their severity,and the presence
of other symptoms meeting criteria for a psychotic dis-
order.No children were diagnosed with COS.Those chil-
dren who reported strong symptoms were 16 times more
likely to have a schizophreniform diagnosis by age 26
years. Furthermore, 90% of the strong symptom chil-
dren had occupational and social dysfunction as adults.
Even those children who reported weak symptoms were
significantly more likely to meet diagnostic criteria for
adult schizophreniform disorder. Forty-two percent of
diagnosed schizophreniform cases at age 26 interviews
were associated with the presence of either weak or
strong symptoms at age 11 years. The authors suggest
that children experiencing hallucinations or delusions
in the absence of a thought disorder may be experienc-
ing prodromal changes, which could lead to the onset
of frank psychotic symptoms.
Rating scales
Once a diagnosis has been established,rating scales are
useful for monitoring symptoms of psychotic disorders
during treatment and over time.Useful pediatric rating
scales include the Child Depression Rating Scale
(CDRS)
65 and the Kiddie Version of the Positive and
Negative Symptoms of Schizophrenia (K-PANSS) for
COS.
66 Rating scales such as the Clinical Global Impres-
sions–Severity and Improvement (CGI-S and CGI-I)
67
and the Clinical Global Assessment of Function
(CGAF)
68 are also useful to measure severity of impair-
ment both at diagnosis and over time for any psychi-
atric disorder.
Research that may inform diagnostic testing 
in the future
Genetics
Evidence from twin, family, and adoption studies indi-
cate genetic factors play an etiological role in schizo-
phrenia.
69A possible susceptibility gene for schizophre-
nia is localized in the region 8p22-8p21.
70 Studies of
children with velocardiofacial syndrome (VCFS) sug-
gest that chromosomal region 22q11.2 may have a role
in development of schizophrenia because the autoso-
mal dominant syndrome sometimes leads to chronic
paranoid schizophrenia.
71 An ongoing study at the
NIMH in 47 subjects with COS demonstrated that 5
patients (10.6%) had cytogenetic abnormalities
72:3
patients had VCFS,1 had Turner’s syndrome (involving
a deletion of part of the long arm of one X chromosome
46,X,i[Xq24]), and 1 had a balanced translocation of
chromosomes 1 and 7.
Smooth-pursuit eye-tracking movements have been pro-
posed as a possible genetic marker for schizophrenia due
to the association of eye-tracking pursuit abnormalities in
adult-onset schizophrenia before and after treatment,in
family members of schizophrenic probands, and in chil-
dren of schizophrenic parents.
73-75 Unique eye-tracking
findings in schizophrenia include specific difficulties in
the high rates of catch-up saccades and the failure to
suppress saccadic anticipation of target motion.
76,77 In a
study of children with COS compared with patients with
adult-onset schizophrenia and their family members,
smooth-pursuit eye-tracking movements and P50 event-
related potential predicted bilineal genetic loading.
78 On
the basis of results of family studies and early genetic
studies, oligogenetics rather than genes of major effect
may better explain complex psychiatric disorders such
as MDD,BPAD,and schizophrenia.
Biological markers
Adolescents with schizotypal disorder had an increase in
minor physical anomalies including abnormal hair
whorls, larger or small head circumference, epicanthal
folds, hypertelorism, asymmetrical or low-seated ears,
curved fifth finger, webbed toes, and other dysmorphic
features,dermatoglyphic asymmetries,and higher mean
cortisol values.
79 Children and adolescents with COS had
higher rates of skin conductance responses and heart
rate compared with controls; however, their skin con-
ductance level was marginally lower and declined more
slowly over time than the controls.
80 Impaired skin con-
ductance rates, more erratic habituation, and smaller
anticipatory heart rate responses to stimuli were also
described. Cerebrospinal fluid monoamine metabolite
concentrations in COS subjects 6 weeks after clinically
effective haloperidol or clozapine treatment did not dif-
fer from drug-free levels.
81 An increase in homovanillic
acid during week 2 of treatment and a decline around
week 6 were also apparent. The haloperidol treatment
group also exhibited a substantial increase in serum pro-
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85lactin levels.All of the above findings are consistent with
findings with schizophrenia of later onset.
Neuroimaging
Magnetic resonance imaging
The NIMH study group on COS has reported sequential
MRI results suggesting brain anatomy changes consis-
tent with adult studies.On the initial scan,children with
COS have larger lateral ventricular volumes as well as
smaller cerebral volumes,
82 whereas the temporal lobe
volumes appear relatively spared.
83A strong association
between smaller cerebral volumes and negative symp-
toms was reported.
84
Adolescents with COS also had larger globus pallidus,
caudate,and putamen volumes at the initial scan.
85  When
the subjects were scanned 1 to 4 years later,subjects with
COS exhibited decreases in total cerebral volume, and
globus pallidus, caudate, and midsagittal thalamic vol-
umes associated with significant increases in ventricular
volume as compared with the control group, which had
similar findings,but no changes in ventricular volumes or
thalamic anatomy.Subjects with COS who were treated
with atypical neuroleptics had even greater decreases in
the globus pallidus and caudate volumes on rescan.The
progressive changes in ventricular volumes and thalamic
area correlated significantly with each other, and the
increases in ventricular volume were significantly related
to prepsychotic adjustment problems rated on the pre-
morbid adjustments scale and Brief Psychiatric Rating
Scale (BPRS).
86A 2-year follow-up study of subjects with
COS showed significant decreases in the volumes of the
right temporal lobe, bilateral superior temporal gyrus,
posterior superior temporal gyrus, right anterior supe-
rior temporal gyrus,and left hippocampus compared with
controls.
87The decline in the right posterior superior tem-
poral gyrus volume was associated with high scores for
positive symptoms.
Of subjects with COS, 12.5% had enlarged cavum septi
pellucidi consistent with a rate found in adult-onset
schizophrenia.
88 The researchers posited that dysgene-
sis of the hippocampus or the corpus callosum could
lead to larger than normal cavum septi pellucidi.In a 2-
year follow-up study of adolescents with COS, healthy
controls showed decrease in cortical gray matter in the
frontal and parietal regions,but patients with very early-
onset schizophrenia had a fourfold greater decrease in
cortical gray matter volume, not only in the frontal and
parietal areas, but also in the temporal lobe volume.
89
The decreases in frontal and temporal gray matter are
consistent with MRI findings in adult-onset schizophre-
nia. Using whole-brain voxel-based morphometric
analyses in both children and adolescents with COS,the
volume of the posterior lateral ventricles was signifi-
cantly increased rather than the anterior regions.
90 In a
controlled comparison of children with COS and chil-
dren diagnosed with PNOS,the two groups were shown
to have similar brain volumes.
91 However,children with
COS had a smaller midsagittal thalamic area compared
with controls and PNOS. Neither group showed a
decrease in the volume of the temporal lobe.
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy (
1H-MRS) performed
on subjects with COS showed significantly lower 
N-acetylaspartate to creatine ratios bilaterally in the
hippocampal area and the dorsolateral prefrontal cortex
compared with normal controls,suggesting malfunction
or neuronal damage.
92 Findings of reduced N-acetylas-
partate in the frontal areas were replicated.
93 Elevated
glutamate/glutamine levels in both frontal lobes and
basal ganglia were detected in 10 children with BPAD.
94
These children also had elevated lipid levels in the
frontal lobes, but not in the temporal areas.The signifi-
cance of the elevated lipids is yet to be determined,but
an increase in excitatory amino acids could be associ-
ated with manic behaviors.
Ultrasound
In examining the ventricular size of fetuses of mothers
with schizophrenia, mild ventriculomegaly was appar-
ent and associated with older mothers and a shorter ges-
tation.
95,96
Psychopharmacological treatment
This section presents pharmacological approaches to
treating psychosis in children,which can be divided into
three categories: (i) COS; (ii) psychosis related to
depression; and (iii) psychosis related to bipolar disor-
der.Neuroleptics may be needed for acute management
of substance-induced psychosis or psychosis related to a
general medical condition or delirium, but the details
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are beyond the scope of this manuscript.PNOS that can-
not be better conceptualized in children and adolescents
as part of the schizophrenia spectrum or a mood disor-
der may be better managed with observation and psy-
chosocial interventions,unless severe aggression or agi-
tation warrants acute use of a neuroleptic.
Treatment of childhood-onset schizophrenia
The majority of data on neuroleptic treatment of schiz-
ophrenia is from adult studies of typical and atypical
neuroleptics. Several neuroleptics are Food and Drug
Administration (FDA)–indicated for psychotic disor-
ders in children and adolescents, but none of the indi-
cations is based on adequate controlled treatment data
in individuals below age 18 years
97: chlorpromazine
(Thorazine
®) for ages ≥ 6 months; thioridazine (Mel-
laril
®) for ages ≥ 2 years; and haloperidol (Haldol
®) for
ages ≥ 3 years.Only two published controlled studies of
typical neuroleptics demonstrated efficacy (both
included haloperidol;one also included loxitane) in the
treatment of COS.Only one published controlled study
of an atypical neuroleptic (clozapine) demonstrated
efficacy in the treatment of COS.Despite the presence
of efficacy data, haloperidol, loxitane, and clozaril are
not considered to be first-line treatments of COS or
any psychosis in children and adolescents because of
their adverse effect (AE) profiles.Atypical agents,such
as risperidone and olanzapine, are more likely first
choices because of easier tolerability, although weight
gain has emerged as a problematic AE.
Typical neuroleptics
Both haloperidol (2-16 mg/day) and loxitane (10-200
mg/day) proved superior to placebo in a 4-week treat-
ment study of 75 adolescents (aged 13-18 years) with
acute schizophrenia.
98 All treatment groups showed
noticeable improvement based on ratings on the BPRS;
subjects rated as severe or very severe tended to show
more improvement on active medication. Sedation
occurred in more than half the subjects on active drug:
about 50% on haloperidol and about 80% on loxitane
experienced sedation.Extrapyramidal symptoms (EPSs)
occurred in about 70% of treated subjects. Haloperidol
later proved superior to placebo based on Clinical Global
Judgment and BPRS ratings in a 10-week,double-blind,
crossover study of 16 children (aged 5-11 years) with
schizophrenia.
99 The dosage of haloperidol ranged from
0.02 to 0.12 mg/kg/day,or 0.5 to 3.5 mg/day.As expected,
EPSs and sedation were the most problematic AEs.
Atypical neuroleptics
Clozapine proved superior to haloperidol for treating
positive and negative psychotic symptoms in a double-
blind, 6-week study of 21 adolescents with schizophre-
nia.
100 As with prior adult studies of clozapine, AEs of
concern included seizures and neutropenia.Several open
studies of clozapine in COS also demonstrated neu-
tropenia, as well as other AEs, such as sedation and
drooling.
101
A review of 15 studies of clozapine in COS, including
controlled and open data,
102 suggested that clozapine
had a greater antipsychotic effect than typical antipsy-
chotics during acute episodes, more improvement in
chronic forms of the illness with prominent negative
symptoms,and “good tolerability”with fewer reports of
EPS.In another review of atypical neuroleptics (includ-
ing clozapine, risperidone, olanzapine, sulpiride,
tiapride,amisulpride,remoxipride,and clothiapine) for
COS,
103 clozapine seemed to have the most robust
effect on the symptoms of COS, and risperidone and
olanzapine also had utility in the treatment of COS.
Overall,clozapine remains a tertiary treatment option
for COS due to its association with potentially danger-
ous AEs, including agranulocytosis, seizures, tachycar-
dia, and arrhythmia.
Risperidone has proven useful in the treatment of a
number of pediatric disorders, but no controlled treat-
ment study of risperidone has been performed for COS.
Open studies of risperidone (up to 10 mg/day) have
been promising for adolescents and children and ado-
lescents with COS based on the CGI-I, BPRS, and K-
PANSS.
104,105 In both studies, the AEs included sedation
and EPS.In a controlled study of risperidone for adults
with first-onset schizophrenia, doses of 2 to 4 mg/day
were superior to 5 to 8 mg/day. By extrapolation, the
open studies of pediatric patients described above likely
utilized too high a dose of risperidone. The only pub-
lished controlled data on risperidone use in pediatric
subjects is a treatment study of adolescents with con-
duct disorder.
106 Weight gain has been the most prob-
lematic AE in two open-label studies of risperidone
treatment of children and adolescents with aggression
and other psychiatric problems.
107,108There have been no published controlled studies of olan-
zapine in COS.Open-label studies of olanzapine for COS
indicate a positive impact on psychotic symptoms,
109-111 and
report primary AEs including weight gain, sedation, and
akathisia,ie,a profile similar to that reported in adults.A
pharmocokinetic study suggested similar olanzapine expo-
sure (defined as area under the concentration–time curve)
in children and adolescents with COS compared with
adults.
112The authors suggested that 10 mg/day olanzapine
is the target dose for treating psychosis in pediatric
patients,consistent with dosing in adults.
There have been no published controlled studies of que-
tiapine in COS.A pharmacokinetic study of quetiapine
in adolescents with psychotic disorders demonstrated
slightly higher quetiapine exposure in adolescents than
in adults.
113 Quetiapine had a beneficial effect on positive
and negative symptoms and was well tolerated;the most
common AEs were insomnia and postural tachycardia.
Ziprasidone was released on the US market in March
2001. No controlled data on ziprasidone treatment for
COS have been published. However, a placebo-con-
trolled study of ziprasidone (5-40 mg/day) was carried
out in 28 children and adolescents (aged 7-17 years) with
Tourette’s syndrome.
114 Somnolence and EPSs were rare
and resolved with dose decrease:1 subject had brief but
severe somnolence on 40 mg/day, and 1 subject experi-
enced akathisia on 40 mg/day.No significant weight gain
was noted in subjects.
Adverse effects
The relative impact of neuroleptics at various receptor
types determines the AEs. Depending on which
dopamine receptor D2 tracts are blocked, AEs of neu-
roleptics include EPS (nigrostriatal pathway),increased
negative symptoms (mesocortical pathway),and hyper-
prolactinemia (tuberoinfundibular pathway). Prolactin
levels were studied in 35 children and adolescents with
COS treated with haloperidol,olanzapine,and/or cloza-
pine.
115 After 6 weeks of treatment, all subjects on
haloperidol and 70% of subjects on olanzapine showed
increased prolactin above the upper limits of normal,
whereas no subjects on clozapine showed increased pro-
lactin level.In addition to an impact on D2,typical neu-
roleptics have an anticholinergic effect (muscarinic
acetylcholine receptor, M1) including sedation, dry
mouth,blurry vision,and constipation;an antihistamin-
ergic effect (histamine receptor, H1) including sedation
and weight gain; and antiadrenergic effects (adrenergic
receptor,  1) including dizziness and hypotension.
Atypical neuroleptics also have capacity to impact M1,
H1, and  1 receptors, and may additionally block D1,
D2, and D4, as well as the serotonin (5-hydroxytrypta-
mine) receptors 5-HT3,5-HT2C,and 5-HT3.In vitro data
suggest that the atypical agents have unique receptor
blockade selectivity.For instance,clozapine blocks all of
the above receptors, whereas risperidone blocks only
5-HT2A, 5-HT2C,  1, and D2 receptors. Serotonergic
blockade by atypical neuroleptics appears to modify
antipsychotic effect and AEs related to dopamine
blockade, and it may have a mood-stabilizing effect.
Significant prolongation of QTc duration (Q-T interval
adjusted for rate) is associated with butyrophenones,
phenothiazines, and pimozide, and does not appear to
be clearly associated with any of the atypical neurolep-
tics.
116 However, electrocardiographic monitoring of
QTc intervals is recommended with ziprasidone.
lthough atypicals contribute to less EPS,cardiac toxicity,
and hyperprolactinemia than typical neuroleptics,atyp-
ical neuroleptics are more likely contribute to promi-
nent weight gain and have higher risk for agranulocy-
tosis than typical neuroleptics. Neuroleptic malignant
syndrome (NMS) is possible with both typical and atyp-
ical neuroleptics.
Treatment of psychosis related 
to pediatric bipolar disorder
No controlled study of pharmacological treatment for
pediatric BPAD with psychosis has been published.The
only controlled medication treatment study to date for
pediatric BPAD included 25 subjects with concomitant
substance-abuse problems.
117 In this study of lithium
monotherapy, bipolar symptoms and substance use
decreased significantly in subjects treated with lithium.
Divalproex,lithium,and carbamazepine each showed a
large effect size (Cohen’s d>1.00) in an open study 42
children and adolescents (aged 8-18 years) with BPAD
based on outcome measures of CGI and Y-MRS.
118
A retrospective chart review of risperidone in juvenile
BPAD indicated improvement in manic and psychotic
symptoms.
119 Open studies of olanzapine in acutely
manic children are promising.
120,121 Because of the robust
antimanic effect demonstrated with atypical neuroleptics
in adults with BPAD,
122 future controlled pediatric stud-
ies of neuroleptics for BPAD are likely.
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with psychotic features
No controlled studies of pharmacological treatment of
psychosis associated with pediatric MDD exist.To date,
only two controlled studies of antidepressants have
shown efficacy in treatment of pediatric MDD. Fluoxe-
tine (5-20 mg) proved superior to placebo in a study of
96 children and adolescents with MDD based on CGI
and Hamilton Depression Rating Scale (HAM-D).
123
Paroxetine proved superior to placebo in a study of 275
adolescents with MDD,according to HAM-D and CGI
rating.
124 An open study of chlorpromazine plus nor-
triptyline for psychotically depressed adolescents
showed some benefit from the combination,
125 however,
neither nortriptyline nor chlorpromazine now appear
desirable as treatment in pediatric mood disorders or
pediatric psychosis because of their side effect profiles.
Psychosocial treatment
To date,there have been no published rigorous studies of
psychosocial or psychotherapy treatments specific to the
psychoses of childhood. Clinical practice standards
include detailed education of the patient and parents
about the illness,the provision of supportive psychother-
apy during the recovery phase of the acute illness, and
practical guidance regarding behavior. Continued sup-
portive work interepisode appears to help patients with
social and developmental crises. Clinicians also act as
advocates with the parents for their patients with schools
and other social agencies to ensure that these children
and adolescents can continue with their education and
that their specials needs are recognized. Families should
be given information about the various patient advocacy
groups,such as the National Alliance for the Mentally Ill.
These groups not only aid on a national and state level to
address the mental health needs of family members, but
also act as a resource for support as these families strug-
gle with these serious illnesses.
Discussion
COS is the best studied of the psychotic disorders of
childhood. The neurobiological studies include neu-
roimaging, family studies (which point to phenotypic
markers),and neurocognitive findings,and strongly sup-
port continuity with the adult form of schizophrenia.Fur-
ther work is needed in describing the neurocognition of
children with affective disorders.The affective psychotic
disorders including BPAD, while indicating continuity
with adult forms, would clearly benefit from a compre-
hensive study, as has been seen in COS. Hopefully, the
controversy over the identification of psychosis and the
diagnosis of these valid disorders will narrow the focus.
Long-term follow-up studies including genetic and other
vulnerabilities,neuroimaging,and neurometabolic stud-
ies will inform researchers and clinicians as to the care
and treatment of these very ill children.There are clearly
too few studies of atypical neuroleptics in the pediatric
population.The long-term effects of chronic treatment in
the developing child are unknown.Careful,well-designed
studies of available medications in the various psychotic
disorders in order to guide appropriate treatment should
be a priority. Novel medications with potential antipsy-
chotic applications, such as dopamine partial agonists,
also require pediatric study. The current trend in treat-
ment research of COS involves large controlled treat-
ment studies of atypical neuroleptics for COS. There is
also need for studies in the psychotherapies and psy-
chosocial treatments to help the patients and their fami-
lies to manage their illness.❏
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Psicosis en niños: diagnóstico y tratamiento
El diagnóstico de la psicosis infantil da origen a un sinnúmero de problemas no resueltos, a pesar
del Texto Revisado del Manual Estadístico de Trastornos Mentales en su cuarta versión (DSM–IV–TR)
que entrega síntomas y definiciones idénticas para niños, adolescentes y adultos. Tanto la vida ima-
ginaria de los niños como los temas del desarrollo del lenguaje y la cognición (incluido el retardo)
dificultan la precisión diagnóstica, particularmente para diferenciar entre la esquizofrenia de ini-
cio infantil (EII) (≤ 12 años), el trastorno afectivo bipolar, el trastorno depresivo mayor, e incluso el
trastorno obsesivo compulsivo y el trastorno por déficit de atención con hiperactividad. La amplia
clasificación que incluye las psicosis no especificadas en otro lugar está siempre disponible para
resolver dificultades que parecen insolubles. Especialmente en las EII, las características típicas, aun-
que no patognomónicas incluyen las dificultades neurocognitivas, las que están presentes a menu-
do en los probandos desde una edad precoz y también en el 30% de los padres no psicóticos. Se
dispone de diversos instrumentos de evaluación y de versiones especializadas de entrevistas semies-
tructuradas principalmente para adultos. Aunque los movimientos de seguimiento ocular pueden
representar un marcador genético de la EII, las etiologías parecen ser más bien oligogenéticas que
debidas a un gen único. Se han identificado marcadores biológicos y neuroimágenes no específi-
cos. Estas psicosis pueden traducir, por lo tanto, un patrón más general de disfunción cerebral. Los
tratamientos con fármacos se utilizan ampliamente, al igual que en los adultos, a pesar de una
escasez de estudios controlados en menores de 18 años. Tampoco se cuenta con investigaciones
rigurosas de tratamientos psicosociales o psicoterapias específicas para las psicosis infantiles.42. Basso MR, Nasrallah HA, Olson SC, Bornstein RA. Cognitive deficits dis-
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Psychoses de l’enfant : diagnostic et traitement
Le diagnostic des psychoses de l’enfant soulève une multitude de problèmes non résolus bien que le Dia-
gnostic and Statistical Manual Of Disorders, 4e édition, Textes Révisés (DSM-IV-TR) en donne des symp-
tômes et des définitions identiques pour les enfants, les adolescents et les adultes. La vie imaginative
des enfants d’une part et les problèmes de développement du langage et de la cognition (y compris le
retard) d’autre part perturbent l’exactitude du diagnostic, en particulier lorsqu'il s'agit de différencier
la schizophrénie survenant dans l’enfance (Childhood-onset schizophrenia, COS) (≤ 12 ans), les troubles
affectifs bipolaires, les dépressions sévères, voire les troubles obsessionnels compulsifs et les troubles à
type de déficit de l’attention/hyperactivité ; la classification fourre-tout, représentée par la psychose non
autrement spécifiée (PNAS), est toujours disponible pour les cas énigmatiques qui se révèlent insolubles.
Les tableaux typiques ou non pathognomoniques, en particulier dans les COS, incluent les difficultés
neurocognitives souvent présentes chez ces patients à partir du plus jeune âge mais également chez
30 % des parents non psychotiques. De nombreux examens de dépistage et des versions spécialisées d’in-
terviews diagnostiques semi-structurées pour adultes sont disponibles. Bien que les mouvements ocu-
laires sans à-coups au cours du test de poursuite oculaire puissent constituer un marqueur génétique de
COS, les étiologies semblent être plutôt polygénétiques que provenant d’un seul gène. Aucun marqueur
biologique ou de neuro-imagerie spécifique de COS n’a été identifié. De telles psychoses pourraient être
un indicateur d’un tableau plus global de dysfonctionnement cérébral. Les traitements médicamenteux
sont globalement les mêmes que chez l'adulte malgré un manque de données contrôlées en dessous de
18 ans, et nous ne disposons toujours pas d’études rigoureuses sur les traitements psychosociaux et la
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